Triple therapy for atrial fibrillation and percutaneous coronary intervention: A contemporary review

Journal of the American College of Cardiology

Volumn 64, Issue 12, 2014, Pages 1270-1280

  Dewilde, Willem J M ^a   Janssen, Paul W A ^b   Verheugt, Freek W A ^c   Storey, Robert F ^d   Adriaenssens, Tom ^e   Hansen, Morten L ^f   Lamberts, Morten ^f   Ten Berg, Jurriën M ^b  

^a AMPHIA HOSPITAL   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c ONZE LIEVE VROUWE GASTHUIS   (Netherlands)

^d UNIVERSITY OF SHEFFIELD   (United Kingdom)

^e UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^f GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

acenocoumarol; clopidogrel; dual antiplatelet therapy; oral anticoagulation; phenprocoumon; platelet aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ANTIVITAMIN K; CLOPIDOGREL; PRASUGREL; TICAGRELOR; ANTICOAGULANT AGENT; TICLOPIDINE; VITAMIN K GROUP;

ANTICOAGULANT THERAPY; BLEEDING; BLOOD TRANSFUSION; CLINICAL EFFECTIVENESS; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; EVIDENCE BASED MEDICINE; HEART ATRIUM FIBRILLATION; HUMAN; INTERNATIONAL NORMALIZED RATIO; PERCUTANEOUS CORONARY INTERVENTION; PRACTICE GUIDELINE; PREVENTION STUDY; REVIEW; STENT THROMBOSIS; THROMBOEMBOLISM; TREATMENT OUTCOME; TREATMENT PLANNING; ANALOGS AND DERIVATIVES; ANTAGONISTS AND INHIBITORS; ATRIAL FIBRILLATION; BLOOD; METABOLISM; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC);

ANTICOAGULANTS; ASPIRIN; ATRIAL FIBRILLATION; HUMANS; PERCUTANEOUS CORONARY INTERVENTION; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TICLOPIDINE; VITAMIN K;

EID: 84908032593     PISSN: 07351097     EISSN: 15583597     Source Type: Journal    
DOI: 10.1016/j.jacc.2014.06.1193     Document Type: Review

References (82)

1. A.J. Camm, G.Y. Lip, and R. De Caterina 2012 focused update of the ESC Guidelines for the Management of Atrial Fibrillation: an update of the 2010 ESC Guidelines for the Management of Atrial Fibrillation Eur Heart J 33 2012 2719 2747
2. R.O. Bonow, B.A. Carabello, and C. Kanu ACC/AHA 2006 guidelines for the management of patients with valvular heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to Revise the 1998 Guidelines for the Management of Patients With Valvular Heart Disease) J Am Coll Cardiol 48 2006 e1 e148
3. R. Nieuwlaat, A. Capucci, A.J. Camm for the European Heart Survey Investigators Atrial fibrillation management: a prospective survey in ESC member countries: the Euro Heart Survey on Atrial Fibrillation Eur Heart J 26 2005 2422 2434
4. G.Y. Lip, K. Huber, and F. Andreotti Consensus document of European Society of Cardiology Working Group on Thrombosis: antithrombotic management of atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing coronary stenting: executive summary - a consensus document of the European Society of Cardiology Working Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous Cardiovascular Interventions (EAPCI) Eur Heart J 31 2010 1311 1318
5. S.C. Smith Jr., T.E. Feldman, and J.W. Hirshfeld Jr. ACC/AHA/SCAI 2005 guideline update for percutaneous coronary intervention - summary article: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (ACC/AHA/SCAI Writing Committee to Update the 2001 Guidelines for Percutaneous Coronary Intervention) J Am Coll Cardiol 47 2006 216 235
6. W.J. Dewilde, T. Oirbans, and F.W. Verheugt Use of clopidogrel with or without aspirin in patients taking oral anticoagulant therapy and undergoing percutaneous coronary intervention: an open-label, randomised, controlled trial Lancet 381 2013 1107 1115
7. B.J. Doyle, C.S. Rihal, D.A. Gastineau, and D.R. Holmes Jr. Bleeding, blood transfusion, and increased mortality after percutaneous coronary intervention: implications for contemporary practice J Am Coll Cardiol 53 2009 2019 2027
8. A.K. Chhatriwalla, A.P. Amin, K.F. Kennedy for the National Cardiovascular Data Registry Association between bleeding events and in-hospital mortality after percutaneous coronary intervention JAMA 309 2013 1022 1029
9. R. Sørensen, M.L. Hansen, and S.Z. Abildstrom Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data Lancet 374 2009 1967 1974
10. E.L. Grove, and R.F. Storey The right oral antithrombotics in acute coronary syndromes Lancet 374 2009 1947 1948
11. W. Dewilde, F.W. Verheugt, N. Breet, J.J. Koolen, and J.M. Ten Berg 'Ins' and 'outs' of triple therapy: Optimal antiplatelet therapy in patients on chronic oral anticoagulation who need coronary stenting Neth Heart J 18 2010 444 450
12. C.T. January, L.S. Wann, and J.S. Alpert 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society J Am Coll Cardiol 2014 Apr 10 [E-pub ahead of print]
13. M. Lamberts, G.H. Gislason, and J.B. Olesen Oral anticoagulation and antiplatelets in atrial fibrillation patients after myocardial infarction and coronary intervention J Am Coll Cardiol 62 2013 981 989
14. Y. Seivani, M. Abdel-Wahab, and V. Geist Long-term safety and efficacy of dual therapy with oral anticoagulation and clopidogrel in patients with atrial fibrillation treated with drug-eluting stents Clin Res Cardiol 102 2013 799 806
15. A. Rubboli, A. Schlitt, T. Kiviniemi for the AFCAS Study Group One-year outcome of patients with atrial fibrillation undergoing coronary artery stenting: an analysis of the AFCAS Registry Clin Cardiol 37 2014 357 364
16. S. Connolly, J. Pogue, R. Hart on behalf of the ACTIVE Investigators Clopidogrel plus aspirin versus oral anticoagulation for atrial fibrillation in the Atrial fibrillation Clopidogrel Trial with Irbesartan for prevention of Vascular Events (ACTIVE W): a randomised controlled trial Lancet 367 2006 1903 1912
17. J.M. Ruiz-Nodar, F. Marín, and J.A. Hurtado Anticoagulant and antiplatelet therapy use in 426 patients with atrial fibrillation undergoing percutaneous coronary intervention and stent implantation implications for bleeding risk and prognosis J Am Coll Cardiol 51 2008 818 825
18. P.P. Karjalainen, P. Porela, and A. Ylitalo Safety and efficacy of combined antiplatelet-warfarin therapy after coronary stenting Eur Heart J 28 2007 726 732
19. M.B. Leon, D.S. Baim, J.J. Popma for the Stent Anticoagulation Restenosis Study Investigators A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting N Engl J Med 339 1998 1665 1671
20. W. Dewilde, and J.M. Ten Berg Trial design: WOEST trial: design and rationale of the WOEST trial: what is the optimal antiplatelet and anticoagulant therapy in patients with oral anticoagulation and coronary stenting Am Heart J 158 2009 713 718
21. J.H. Chesebro, G. Knatterud, and R. Roberts Thrombolysis In Myocardial Infarction (TIMI) trial, phase I: a comparison between intravenous tissue plasminogen activator and intravenous streptokinase. Clinical findings through hospital discharge Circulation 76 1987 142 154
22. R. Mehran, S.V. Rao, and D.L. Bhatt Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium Circulation 123 2011 2736 2747
23. K.A. Fox Dual or single antiplatelet therapy with anticoagulation? Lancet 381 2013 1080 1081
24. L. Wallentin, S. Yusuf, and M.D. Ezekowitz Efficacy and safety of dabigatran compared with warfarin at different levels of international normalised ratio control for stroke prevention in atrial fibrillation: an analysis of the RE-LY trial Lancet 376 2010 975 983
25. S. Yusuf, S.R. Mehta, S. Chrolavicius for the Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators Comparison of fondaparinux and enoxaparin in acute coronary syndromes N Engl J Med 354 2006 1464 1476
26. G.W. Stone, B.T. McLAurin, D.A. Cox for the ACUITY Investigators Bivalirudin for patients with acute coronary syndromes N Engl J Med 355 2006 2203 2216
27. M. Moscucci, K.A. Fox, and C.P. Cannon Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE) Eur Heart J 24 2003 1815 1823
28. H.D. White Strategies to minimize bleeding complications of percutaneous coronary intervention Curr Opin Cardiol 24 2009 273 278
29. M.A. Mamas, K. Ratib, and H. Routledge Influence of access site selection on PCI-related adverse events in patients with STEMI: meta-analysis of randomised controlled trials Heart 98 2012 303 311
30. S.V. Manoukian Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction Am J Cardiol 104 Suppl 5 2009 9C 15C
31. M. Gilard, D. Blanchard, G. Helft for the STENTICO Investigators Antiplatelet therapy in patients with anticoagulants undergoing percutaneous coronary stenting (from STENTIng and oral antiCOagulants [STENTICO]) Am J Cardiol 104 2009 338 342
32. J.L. Mega, E. Braunwald, S.D. Wiviott for the ATLAS ACS 2-TIMI 51 Investigators Rivaroxaban in patients with a recent acute coronary syndrome N Engl J Med 366 2012 9 19
33. J.H. Alexander, R.D. Lopes, S. James for the APPRAISE-2 Investigators Apixaban with antiplatelet therapy after acute coronary syndrome N Engl J Med 365 2011 699 708
34. G. Ndrepepa, T. Schuster, and M. Hadamitzky Validation of the Bleeding Academic Research Consortium definition of bleeding in patients with coronary artery disease undergoing percutaneous coronary intervention Circulation 125 2012 1424 1431
35. The GUSTO Investigators An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction N Engl J Med 329 1993 673 682
36. A. Rubboli, J.L. Halperin, and K.E. Airaksinen Antithrombotic therapy in patients treated with oral anticoagulation undergoing coronary artery stenting. An expert consensus document with focus on atrial fibrillation Ann Med 40 2008 428 436
37. T. Gomes, M.M. Mamdani, A.M. Holbrook, J.M. Paterson, C. Hellings, and D.N. Juurlink Rates of hemorrhage during warfarin therapy for atrial fibrillation CMAJ 185 2013 E121 E127
38. P. Roy, L. Bonello, and R. Torguson Impact of "nuisance" bleeding on clopidogrel compliance in patients undergoing intracoronary drug-eluting stent implantation Am J Cardiol 102 2008 1614 1617
39. E. Nikolsky, R. Mehran, and G. Dangas Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach Eur Heart J 28 2007 1936 1945
40. A. Chase, E.B. Fretz, and W.P. Warburton Association of the arterial access site at angioplasty with transfusion and mortality: the M.O.R.T.A.L study (Mortality benefit Of Reduced Transfusion after percutaneous coronary intervention via the Arm or Leg) Heart 94 2008 1019 1025
41. R. Pisters, D.A. Lane, R. Nieuwlaat, C.B. de Vos, H.J. Crijns, and G.Y. Lip A novel user-friendly score (HAS-BLED) to assess 1-year risk of major bleeding in patients with atrial fibrillation: the Euro Heart Survey Chest 138 2010 1093 1100
42. P. Gallego, V. Roldán, and J.M. Torregrosa Relation of the HAS-BLED bleeding risk score to major bleeding, cardiovascular events, and mortality in anticoagulated patients with atrial fibrillation Circ Arrhythm Electrophysiol 5 2012 312 318
43. W. Dewilde, P. Janssen, J. Kelder for the WOEST study investigators Uninterrupted oral anticoagulation versus bridging in patients with long-term oral anticoagulation during percutaneous coronary intervention Eurointervention 2014 Jun 28 [E-pub ahead of print]
44. H. Lahtela, A. Rubboli, A. Schlitt for the AFCAS (Management of patients with Atrial Fibrillation undergoing Coronary Artery Stenting) study group Heparin bridging vs. uninterrupted oral anticoagulation in patients with atrial fibrillation undergoing coronary artery stenting: results from the AFCAS registry Circ J 76 2012 1363 1368
45. J.M. ten Berg, J.C. Kelder, and M.J. Suttorp Effect of coumarins started before coronary angioplasty on acute complications and long-term follow-up: a randomized trial Circulation 102 2000 386 391
46. T. Kiviniemi, P. Karjalainen, and M. Pietilä Comparison of additional versus no additional heparin during therapeutic oral anticoagulation in patients undergoing percutaneous coronary intervention Am J Cardiol 110 2012 30 35
47. S.B. Pancholy, I. Ahmed, O.F. Bertrand, and T. Patel Frequency of radial artery occlusion after transradial access in patients receiving warfarin therapy and undergoing coronary angiography Am J Cardiol 113 2014 211 214
48. M. Gilard, B. Arnaud, and J. Cornily Influence of omeprazole on the antiplatelet action of clopidogrel associated with aspirin: the randomized, double-blind OCLA (Omeprazolee CLopidogrel Aspirin) study J Am Coll Cardiol 51 2008 256 260
49. J.J. Focks, M.A. Brouwer, M.G. van Oijen, A. Lanas, D.L. Bhatt, and F.W. Verheugt Concomitant use of clopidogrel and proton pump inhibitors: impact on platelet function and clinical outcome- a systematic review Heart 99 2013 520 527
50. D.L. Bhatt, B.L. Cryer, C.F. Contant for the COGENT Investigators Clopidogrel with or without omeprazolee in coronary artery disease N Engl J Med 363 2010 1909 1917
51. M.L. O'Donoghue, E. Braunwald, and E.M. Antman Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials Lancet 374 2009 989 997
52. J.L. Mega, S.L. Close, and S.D. Wiviott Cytochrome p-450 polymorphisms and response to clopidogrel N Engl J Med 360 2009 354 362
53. D. Aradi, R.F. Storey, and A. Komócsi Expert position paper on the role of platelet function testing in patients undergoing percutaneous coronary intervention Eur Heart J 35 2014 209 215
54. G.W. Stone, B. Witzenbichler, and G. Weisz Platelet reactivity and clinical outcomes after coronary artery implantation of drug-eluting stents (ADAPT-DES): a prospective multicentre registry study Lancet 382 2013 614 623
55. D. Sibbing, N. von Beckerath, and T. Morath Oral anticoagulation with coumarin derivatives and antiplatelet effects of clopidogrel Eur Heart J 31 2010 1205 1211
56. Wallentin L, Becker RC, Budaj A, et al., for the PLATO Investigators, Freij A, Thorsén M. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009;361:1045-57.
57. S.D. Wiviott, E. Braunwald, C.H. McCabe for the TRITON-TIMI 38 Investigators Prasugrel versus clopidogrel in patients with acute coronary syndromes N Engl J Med 357 2007 2001 2015
58. S. Yusuf, F. Zhao, S.R. Mehta, S. Chrolavicius, G. Tognoni, K.K. Fox Clopidogrel in Unstable Angina to Prevent Recurrent Events Trial Investigators Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation N Engl J Med 345 2001 494 502
59. M.L. Hansen, R. Sørensen, and M.T. Clausen Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation Arch Intern Med 170 2010 1433 1441
60. J.L. Orford, P. Fasseas, and S. Melby Safety and efficacy of aspirin, clopidogrel, and warfarin after coronary stent placement in patient with an indication for anticoagulation Am Heart J 147 2004 463 467
61. R.F. Van Es, J.J.C. Jonker, F.W.A. Verheugt, J.W. Deckers, D.E. Grobbee for the Antithrombotics in the Secondary Prevention of Events in Coronary Thrombosis-2 (ASPECT-2) Research Group Aspirin and coumadin after acute coronary syndromes (the ASPECT-2 study): a randomised controlled trial Lancet 360 2002 109 113
62. M. Hurlen, M. Abdelnoor, P. Smith, J. Erikssen, and H. Arnesen Warfarin, aspirin, or both after myocardial infarction N Engl J Med 347 2002 969 974
63. C. Patrono, and F. Andreotti Antithrombotic therapy for patients with atrial fibrillation and atherothrombotic vascular disease: striking the right balance between efficacy and safety Circulation 128 2013 684 686
64. L.A. García Rodríguez, L. Cea Soriano, C. Hill, and S. Johansson Increased risk of stroke after discontinuation of acetylsalicylic acid: a UK primary care study Neurology 76 2011 740 746
65. L.A. Rodríguez, L. Cea-Soriano, E. Martín-Merino, and S. Johansson Discontinuation of low dose aspirin and risk of myocardial infarction: case-control study in UK primary care BMJ 343 2011 d4094
66. B.A. Steinberg, S. Kim, J.P. Piccini for the ORBIT-AF Investigators and Patients Use and associated risks of concomitant aspirin therapy with oral anticoagulation in patients with atrial fibrillation: insights from the Outcomes Registry for Better Informed Treatment of Atrial Fibrillation (ORBIT-AF) Registry Circulation 128 2013 721 728
67. M. Lamberts, G.H. Gislason, and G.Y. Lip Antiplatelet therapy for stable coronary artery disease in atrial fibrillation patients on oral anticoagulant: a nationwide cohort study Circulation 129 2014 1577 1585
68. D.P. Faxon, J.W. Eikelboom, and P.B. Berger Consensus document: antithrombotic therapy in patients with atrial fibrillation undergoing coronary stenting. A North-American perspective Thromb Haemost 106 2011 572 584
69. T. Palmerini, A.J. Kirtane, and P.W. Serruys Stent thrombosis with everolimus-eluting stents: meta-analysis of comparative randomized controlled trials Circ Cardiovasc Interv 5 2012 357 364
70. F. Feres, R.A. Costa, A. Abizaid for the OPTIMIZE Trial Investigators Three vs twelve months of dual antiplatelet therapy after zotarolimus-eluting stents: the OPTIMIZE randomized trial JAMA 310 2013 2510 2522
71. H.C. Gwon, J.Y. Hahn, and K.W. Park Six-month versus 12-month dual antiplatelet therapy after implantation of drug-eluting stents: the Efficacy of Xience/Promus Versus Cypher to Reduce Late Loss After Stenting (EXCELLENT) randomized, multicenter study Circulation 125 2012 505 513
72. M. Valgimigli, G. Campo, M. Monti for the Prolonging Dual Antiplatelet Treatment After Grading Stent-Induced Intimal Hyperplasia Study (PRODIGY) Investigators Short- versus long-term duration of dual-antiplatelet therapy after coronary stenting: a randomized multicenter trial Circulation 125 2012 2015 2026
73. B.K. Kim, M.K. Hong, D.H. Shin for the RESET Investigators A new strategy for discontinuation of dual antiplatelet therapy: the RESET Trial (REal Safety and Efficacy of 3-month dual antiplatelet Therapy following Endeavor zotarolimus-eluting stent implantation) J Am Coll Cardiol 60 2012 1340 1348
74. J.S. Kim, I.K. Jang, and C. Fan Evaluation in 3 months duration of neointimal coverage after zotarolimus-eluting stent implantation by optical coherence tomography: the ENDEAVOR OCT trial J Am Coll Cardiol Intv 2 2009 1240 1247
75. N. Sarafoff, A. Martischnig, and J. Wealer Triple therapy with aspirin, prasugrel, and vitamin K antagonists in patients with drug-eluting stent implantation and an indication for oral anticoagulation J Am Coll Cardiol 61 2013 2060 2066
76. S.J. Connolly, M.D. Ezekowitz, S. Yusuf for the RE-LY Steering Committee and Investigators Dabigatran versus warfarin in patients with atrial fibrillation N Engl J Med 361 2009 1139 1151
77. M.R. Patel, K.W. Mahaffey, J. Garg for the ROCKET AF Investigators Rivaroxaban versus warfarin in nonvalvular atrial fibrillation N Engl J Med 365 2011 883 891
78. C.B. Granger, J.H. Alexander, J.J. McMurray for the ARISTOTLE Committees and Investigators Apixaban versus warfarin in patients with atrial fibrillation N Engl J Med 365 2011 981 992
79. J. Oldgren, A. Budaj, C.B. Granger for the RE-DEEM Investigators Dabigatran vs. placebo in patients with acute coronary syndromes on dual antiplatelet therapy: a randomized, double-blind, phase II trial Eur Heart J 32 2011 2781 2789
80. ClinicalTrials.gov. PIONEER-AF-PCI trial: An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention. Available at: http://clinicaltrials.gov/ct2/show/NCT01830543. Accessed July 17, 2014.
81. ClinicalTrials.gov. REDUAL PCI: Randomized Evaluation of Dual Therapy with Dabigatran vs. Triple Therapy Strategy with Warfarin in Patients with NVAF that have undergone PCI with Stenting. Available at: http://clinicaltrials.gov/ct2/results?term=REDUAL&Search=Search. Assessed August 25, 2014.
82. ClinicalTrials.gov. ISAR-TRIPLE: Triple therapy in Patients on Oral Anticoagulation After Drug Eluting Stent Implantation: trial design. Available at: http://clinicaltrials.gov/ct2/show/NCT00776633. Accessed July 17, 2014.